Inhalation & Respiratory Drug Delivery Congress 2016

Day 1 – Development And Formulation Of Inhaled Therapies

·         Combination product design

·         Achieving an inhaled insulin product

·         Developing a generic inhaled product

·         Regulatory considerations for inhaled therapies

·         Alternative therapeutic fields: inhaled antibiotics

·         Future directions in inhalation and respiratory drug delivery research

Day 2 – Inhalation Devices And Analytics

·         Novel technologies for pulmonary and nasal delivery

·         The challenge of developing inhalation devices

o    Dry-powder inhalers (DPIs)

o    Metered-dose inhalers (MDIs)

o    Nebulisers

·         Improving patient adherence with product design

·         Establishing clear relationships between in vitro and in vivo data

·         Analytical tools for inhaled medicines

• Frank Thielmann, Novartis, Operational Lead, Inhalation New Solids, Switzerland

• Peter Daley-Yates, GlaxoSmithKline, Director Clinical Pharmacology, UK

• Jan Olof Svensson, AstraZeneca, Principal Scientist Inhalation, Sweden

• Andy West, GlaxoSmithKline, Biological Mass Spectrometry Section Head, UK

• Robert Price, University of Bath, Professor in Pharmaceutics, UK

• Louise Sheridan, AstraZeneca, Global Device Director, UK